Navigation Links
Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
Date:3/3/2008

significant improvements in pain response were observed in 76.7% of patients at the 5 mg dose (p = 0.02), 79.1% of patients at the 2.5 mg dose (p = 0.01) and 67.4% of patients at the 1.25 mg dose (p = 0.18), compared to 51.3% of patients receiving placebo. Using survival analysis for pain relief response, all three dose groups were statistically superior (p < 0.05) to placebo during the 4-hour post-treatment time period that the patients remained in the clinic.

Primary Efficacy Endpoint -- Pain Relief at 2-Hours Post-Dose

Number of Patients Achieving % p-value

Treatment Patients Pain Relief Pain-Relief vs Placebo

Placebo 39 20 51.3% na

1.25 mg 43 29 67.4% 0.18

2.5 mg 43 34 79.1% 0.01*

5 mg 43 33 76.7% 0.02*

* Statistically significant (p < 0.05)

Additional Efficacy Endpoints

Additional measures of efficacy included the achievement of a pain-free response, in which a patient has a post-dose pain score of 0 (or "no") headache pain. In the trial, AZ-104 showed statistically significant differences from placebo in this measure at the 2-hour time point with 30% of patients achieving pain-free status at the 2.5 mg dose (p = 0.01) and 28% at the 1.25 mg dose (p = 0.02). While the 5.0 mg dose was numerically superior to placebo with 21% pain-free, this group did not achieve a statistically significant response, compared to placebo (p = 0.12). The rate of pain-free response at 2 hours in patients receiving placebo was 8%. Using survival analysis for pain free response, all three dose groups were statistically superior (p < 0.05) to placebo during the 4-hour post-treatment time period that the patients remained in the clinic.

A commonly used measure of
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... OAKS, Calif., April 21, 2015 Amgen (NASDAQ: ... first quarter of 2015. Key results include: , ... of 2014 to $5,033 million, with 12 percent product ... Prolia ® (denosumab), EPOGEN ® (epoetin alfa), ... Unfavorable changes in foreign exchange rates impacted total revenue ...
(Date:4/21/2015)... , 21. April 2015  CorTechs Labs, ... quantitative Analyse des Hirnvolumens freut sich, eine ... Pharmaunternehmen, bekannt geben zu können. Die Unternehmen ... des Hirnvolumens zusammenarbeiten, der die Identifizierung, Messung ... Patienten mit multipler Sklerose als Ziel hat. ...
(Date:4/21/2015)... -- Lincoln Computer Services has taken a proactive approach to ... LCS donated 10 laptops and carts to the Good ... Home at Riverdale by RiverSpring ... is a creative, non-pharmacological approach to Alzheimer,s care that ... in the morning, start their day off in a ...
Breaking Medicine Technology:Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2Lincoln Continues Support of the Community: Donates 10 Laptops for Alzheimer's Program 2
... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will present updated results from its,Phase 2 ... a,poster discussion session at the International Association for ... on Lung Cancer in Seoul, Korea.,Details follow: ...
... - Positive Phase 2 Clinical Trial Results from PI-88 in ... $92.4 million in Raised Capital Highlight the Year ... PGL; Nasdaq: PGLA) today released its,financial results for the fiscal ... * Announced positive results from a Phase 2, 172 ...
Cached Medicine Technology:Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 2Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer 3Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 2Progen Pharmaceuticals Announces Fiscal 2007 Financial Results 3
(Date:4/21/2015)... April 21, 2015 Displays & Exhibits, ... in the trade show exhibit building industry, announced a ... sales offices of Absolute Exhibits in Tustin, California.“It is ... shoppers to observe the variation in quality as offered ... Exhibits,” explained Zenos Adduru. Mr. Adduru is the new ...
(Date:4/21/2015)... San Francisco, CA and Orlando, FL (PRWEB) April ... for Behavioral Health (National Council) will honor Dina ... Support Services for PREP (Prevention and Recovery in ... the National Council Award of Excellence: Peer Specialist ... NatCon15 awards ceremony, known as the Oscars of ...
(Date:4/21/2015)... Henry Mayo Newhall Hospital, located in ... to automatically send continuation of care documents (CCDs). ... improve communication with clinics and other ambulatory practices, they ... solution. , “Provider Alert will enable the physician ... they need to provide continuing care in real time,” ...
(Date:4/21/2015)... April 21, 2015 Grafika is pleased ... printer, Offset Impressions. , “We’re excited about ... of printing capabilities and knowledgeable team members,” according to ... allows us to offer an ever wider breadth of ... packaging, and specialty services we already offer. It ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 2Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 3Health News:The National Council for Behavioral Health Honors Felton Institute’s PREP Program Coordinator with Prestigious Peer Specialist of the Year Award 4Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... losing in a way that's making other communities in the ... a town of 80,000 outside Boston, have been taking part ... eating habits that stay with them throughout their lives. As ... those in nearby towns, and as they learn to eat ...
... felt on the world fashion map, it is attracting ... the ramp here but also try their luck in ... matured as designers stopped copying Western motifs blindly. India ... as becoming a profitable business destination for international buyers. ...
... functions may be vulnerable to Alzheimers disease if they ... blood vessels in the brain, says a study ... in the Journal of Neuroimaging, also suggests that people ... the disease than their peers. ,Alzheimers ...
... Elevated CO2 is considered to be a serious catalyst ... the ecosystem , including the insect-plant food chain link.Safeguarding ... and national economies. ,In research to be presented ... Plant Biologists in Chicago (July 7-11, 2007), scientists will ...
... who received the world's first face transplant 18 months ago said ... herself in the mirror with a combination of sadness and wonder. ... who have a face, a smile, facial expressions which allow them ... in an interview published in Saturday's edition of Le Monde. ...
... Africa on Friday after they came into contact with an ... ,Inspector Juanita Kilian said police had received a complaint ... of Johannesburg, about a "suspicious" envelope, she told public radio. ... this stage we cannot confirm that the contents were anthrax," ...
Cached Medicine News:Health News:Somerville, A Town Committed to Tackle Obesity Among Kids 2Health News:Somerville, A Town Committed to Tackle Obesity Among Kids 3Health News:Indian Fashion Beckons International Models 2Health News:Elevated Carbondioxide may Have Negative Impact on Ecosystem 2Health News:World's First Face Transplant Patient Feels She is Alive Again 2
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... Digisonics has set the standard in ... review station, the only fully integrated ... multi-modality reporting., ,DigiView cardiology solutions bring ... professional reporting choices, an integrated clinical ...
... The menu-driven Vapro osmometer determines osmolality ... natural equilibrium. ,What you don't get are ... particles, or other conditions that interfere with ... percent in the clinical range) Vapro osmometer ...
Medicine Products: